When will Genscript report earnings and why it matters for 1548.HK stock?

Genscript's earnings are scheduled around **11 Mar 2026** (company guidance window), with formal notice on **15 Mar 2026 UTC**. Results matter because management guidance will affect Biologics Development revenue forecasts and the stock's short-term direction on the HKSE

What is Meyka AI's outlook for 1548.HK stock?

Meyka AI's model projects a **Yearly HK$12.93** for 1548.HK stock, implying an **+8.81%** upside versus **HK$11.88**. This outlook combines financials, sector trends, and analyst inputs, but it is not a guarantee

Which metrics should investors watch in the 1548.HK earnings report?

Watch revenue by segment, Biologics Development margins, order backlog, and free cash flow. Also note EPS trends and management guidance, as these items directly affect 1548.HK stock valuation and forward multiples

How does sector performance affect 1548.HK stock ahead of earnings?

The Healthcare sector in Hong Kong has been weak recently, down **-8.20%** over one month. Sector pressure can amplify earnings surprises, increasing volatility for 1548.HK stock on release

HK Stocks

1548.HK stock up pre-market ahead of 11 Mar 2026 earnings: guidance in focus

ByDanny Kontos March 10, 2026

We see Genscript Biotech Corporation (1548.HK) trading in the pre-market at HK$11.88 as investors position for the company’s earnings on 11 Mar 2026. This 1548.HK stock move follows a +3.94% intraday uptick on volume of 9.88M shares. The earnings announcement on 15 Mar 2026 (UTC) will be the main catalyst, with market attention on revenue mix and Biologics Development margins. We highlight valuation, Meyka model forecasts and likely guidance clues that could move the stock in Hong Kong trading hours